Journal
NEUROLOGY
Volume 76, Issue 3, Pages 273-279Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318207b073
Keywords
-
Categories
Funding
- Janssen
- Eisai Inc.
- Pfizer Inc
- National Health Service UK (NHS)
- MRC
- Epilepsy Research Foundation
- Epilepsy Action
- GlaxoSmithKline
- sanofi-aventis
- UCB
- NHS
- NIHR
- Epilepsy Action UK
- Epilepsy Research UK
- Leukaemia Research Fund
- NIH (NINDS)
- CDC
- Hotchkiss Neurological Institute
- AUCD
- Maternal and Child Health Bureau
- Centers for Disease Control and Prevention [MM-0322]
- UK Research Medical Council [G9125317]
- NIH (NICHD)
- MRC [G0800792] Funding Source: UKRI
- Medical Research Council [G0800792] Funding Source: researchfish
Ask authors/readers for more resources
Objective: Adverse effects (AEs) are a major concern when starting antiepileptic drug (AED) treatment. This study quantified the extent to which AE reporting in people with new-onset seizures started on AEDs is attributable to the medication per se, and investigated variables contributing to AE reporting. Methods: We pooled data from 2 large prospective studies, the Multicenter Study of Early Epilepsy and Single Seizures and the Northern Manhattan Study of incident unprovoked seizures, and compared adverse event profile (AEP) total and factor scores between adult cases prescribed AEDs for new-onset seizures and untreated controls, adjusting for several demographic and clinical variables. Differences in AEP scores were also tested across different AED monotherapies and controls, and between cases and controls grouped by number of seizures. Results: A total of 212 cases and 206 controls were identified. Most cases (94.2%) were taking low AED doses. AEP scores did not differ significantly between the 2 groups. Depression, female gender, symptomatic etiology, younger seizure onset age, >= 2 seizures, and history of febrile seizures were associated with higher AEP scores. There were no significant differences in AEP scores across different monotherapies and controls. AEP scores increased in both cases and controls with increasing number of seizures, the increment being more pronounced in cases. Conclusions: When AED treatment is started at low doses following new-onset seizures, AE reporting does not differ from untreated individuals. Targeting specific factors affecting AE reporting could lead to improved tolerability of epilepsy treatment. Neurology (R) 2011; 76:273-279
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available